Overall Survival statistical summary
Variable | Total | Univariate Cox models | Multivariate Cox models | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Clinical model | Clinical and CD8 model | Clinical and HLA model | Clinical and HLA/CD8 model | |||||||||||||||||||
Hratio | 95% IC | p | adj padj padj p | Hratio | 95% IC | p | adj padj padj p | Hratio | 95% IC | p | adj padj padj p | Hratio | 95% IC | p | adj padj padj p | Hratio | 95% IC | p | adj padj padj p | |||
Age (%) | median (range) | 63 (29–83) | 1.015 | [0.993;1.038] | 0.18 | 0.42 | 1.018 | [0.995;1.041] | 0.13 | 0.36 | 1.012 | [0.990;1.035] | 0.3 | 0.57 | 1.016 | [0.993;1.040] | 0.17 | 0.42 | 1.015 | [0.993;1.039] | 0.18 | 0.42 |
continuous | mean(sd) | 61.73 (11.47) | ||||||||||||||||||||
Sex(%) | Female | 33 (28.95) | 1 | 1 | 1 | 1 | 1 | |||||||||||||||
Male | 81 (71.05) | 0.762 | [0.469;1.238] | 0.27 | 0.55 | 0.77 | [0.464;1.282] | 0.32 | 0.57 | 0.771 | [0.460;1.292] | 0.32 | 0.57 | 0.759 | [0.447;1.289] | 0.31 | 0.57 | 0.686 | [0.397;1.185] | 0.18 | 0.42 | |
Chemo(%) | No | 36 (31.58) | 1 | 1 | 1 | 1 | 1 | |||||||||||||||
Yes | 78 (68.42) | 0.812 | [0.502;1.314] | 0.4 | 0.6 | 0.73 | [0.432;1.231] | 0.24 | 0.53 | 0.928 | [0.534;1.612] | 0.79 | 0.92 | 0.744 | [0.438;1.262] | 0.27 | 0.55 | 0.793 | [0.464;1.355] | 0.4 | 0.6 | |
KRAS | No | 79 (69.30) | 1 | – | – | – | – | |||||||||||||||
Yes | 35 (30.70) | 1.979 | [1.211;3.233] | 0.006 | 0.05 | |||||||||||||||||
BRAF+KRAS | No | 76 (66.67) | 1 | 1 | 1 | 1 | 1 | |||||||||||||||
Yes | 38 (33.33) | 1.737 | [1.07;2.82] | 0.03 | 0.13 | 2.06 | [1.223;3.487] | 0.007 | 0.05 | 2.171 | [1.281;3.682] | 0.004 | 0.05 | 1.882 | [1.104;3.230] | 0.02 | 0.1 | 1.716 | [0.992;2.968] | 0.05 | 0.2 | |
Tumor side | Right | 25 (21.93) | 1 | 1 | 1 | 1 | 1 | 1 | ||||||||||||||
Left | 89 (78.07) | 0.92 | [0.528;1.604] | 0.77 | 0.91 | 1.304 | [0.721;2.359] | 0.38 | 0.6 | 1.151 | [0.639;2.074] | 0.64 | 0.79 | 1.334 | [0.735;2.421] | 0.34 | 0.58 | 1.208 | [0.671;2.175] | 0.53 | 0.7 | |
CD8 invasive margin continuous | 0.66 | [0.500;0.866] | 0.003 | 0.05 | 0.644 | [0.477;0.869] | 0.004 | 0.05 | ||||||||||||||
CD8 tumor core continuous | 0.906 | [0.679;1.209] | 0.5 | 0.67 | ||||||||||||||||||
CD8 total continuous | 0.705 | [0.534;0.926] | 0.01 | 0.06 | ||||||||||||||||||
HLA score | 41 (37.27) | 1 | 1 | |||||||||||||||||||
69 (62.73) | 0.593 | [0.366;0.959] | 0.03 | 0.13 | 0.631 | [0.379;1.050] | 0.08 | 0.25 | ||||||||||||||
HLA/CD8 combined | Low/Low | 24 (21.82) | 1 | 1 | ||||||||||||||||||
Others | 86 (78.18) | 0.391 | [0.230;0.663] | 0.0005 | 0.02 | 0.415 | [0.234;0.737] | 0.003 | 0.05 | |||||||||||||
PDL1 TC SP142 | High | 18 | 1 | |||||||||||||||||||
Low | 5 (4.39) | 0.6 | [0.147;2.443] | 0.48 | 0.66 | |||||||||||||||||
PDL1 invasive margin SP142 | High | 34 (29.82) | 1 | |||||||||||||||||||
Low | 80 (70.18) | 0.791 | [0.463;1.348] | 0.39 | 0.6 | |||||||||||||||||
CD163 invasive margin | 1 | 27 (23.68) | 1 | |||||||||||||||||||
2 | 42 (36.84) | 0.719 | [0.408;1.266] | 0.25 | 0.54 | |||||||||||||||||
3 | 32 (28.07) | 0.807 | [0.443;1.467] | 0.48 | 0.66 | |||||||||||||||||
FoxP3 invasive margin | 0 | 45 (39.47) | 1 | |||||||||||||||||||
1 | 20 (17.54) | 1.182 | [0.654;2.135] | 0.58 | 0.73 | |||||||||||||||||
NKp46 | Low | 50 (49.50) | 1 | |||||||||||||||||||
High | 45 (50.50) | 1.024 | [0.640;1.636] | 0.93 | 0.98 | |||||||||||||||||
AUC | – | – | 0.63 | 0.72 | 0.67 | 0.72 |